| Q97883035 | Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population |
| Q46091045 | Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing |
| Q36125427 | Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. |
| Q37624344 | Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. |
| Q34409335 | Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). |
| Q54659626 | Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation. |
| Q37358921 | Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation |
| Q54671417 | Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients. |
| Q52690736 | Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. |
| Q89796128 | Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning |
| Q36987975 | Optimizing drug development of anti-cancer drugs in children using modelling and simulation |
| Q48333770 | Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram. |
| Q38003177 | Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants |
| Q36777485 | Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II. |
| Q89068750 | Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents |
| Q38721390 | Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia |
| Q92086215 | Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients |
| Q50924228 | Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation. |
| Q35126138 | Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. |
| Q47173685 | Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing |
| Q37224427 | Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients |